Trade Report: Today, Swiss National Bank Reduced the position of Illumina Inc. (ILMN)

Today, Swiss National Bank Reduced the position of Illumina Inc. (ILMN)

Swiss National Bank reduced its stake in shares of Illumina Inc. (NASDAQ:ILMN) by 0.7% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 407,445 shares of the life sciences company’s stock after selling 3,000 shares during the period. Swiss National Bank’s holdings in Illumina were worth $74,016,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of ILMN. Capital Research Global Investors boosted its stake in Illumina by 17.1% in the second quarter. Capital Research Global Investors now owns 13,085,071 shares of the life sciences company’s stock valued at $1,836,882,000 after buying an additional 1,910,346 shares during the last quarter. Capital World Investors boosted its stake in Illumina by 218.0% in the second quarter. Capital World Investors now owns 1,463,000 shares of the life sciences company’s stock valued at $205,376,000 after buying an additional 1,003,000 shares during the last quarter. Baillie Gifford & Co. boosted its stake in Illumina by 3.8% in the second quarter. Baillie Gifford & Co. now owns 18,615,061 shares of the life sciences company’s stock valued at $2,613,182,000 after buying an additional 682,010 shares during the last quarter. Rockefeller Financial Services Inc. boosted its stake in Illumina by 11,812.5% in the second quarter. Rockefeller Financial Services Inc. now owns 271,962 shares of the life sciences company’s stock valued at $38,177,000 after buying an additional 269,679 shares during the last quarter. Finally, American Capital Management Inc. bought a new stake in Illumina during the third quarter valued at $43,373,000. Hedge funds and other institutional investors own 92.98% of the company’s stock.

Illumina Inc. (NASDAQ:ILMN) opened at 136.18 on Tuesday. The company has a market capitalization of $20.00 billion, a PE ratio of 45.70 and a beta of 1.24. The firm’s 50-day moving average is $139.08 and its 200-day moving average is $152.96. Illumina Inc. has a 52-week low of $127.10 and a 52-week high of $196.47.

Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, November 1st. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.87 by $0.10. Illumina had a return on equity of 23.76% and a net margin of 18.72%. The company had revenue of $607 million for the quarter, compared to analysts’ expectations of $628.06 million. During the same period last year, the business earned $0.80 EPS. Illumina’s quarterly revenue was up 10.4% compared to the same quarter last year. On average, equities research analysts forecast that Illumina Inc. will post $3.32 EPS for the current year.

Several equities research analysts have weighed in on ILMN shares. Vetr upgraded shares of Illumina from a “buy” rating to a “strong-buy” rating and set a $154.48 price objective for the company in a research report on Tuesday, November 1st. Zacks Investment Research lowered shares of Illumina from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 19th. CL King lowered shares of Illumina from a “buy” rating to a “neutral” rating in a research note on Monday, August 22nd. Cantor Fitzgerald reduced their target price on shares of Illumina from $165.00 to $155.00 and set a “hold” rating on the stock in a research note on Tuesday, October 11th. Finally, Argus raised their target price on shares of Illumina from $175.00 to $185.00 and gave the company a “buy” rating in a research note on Monday, August 8th. Four analysts have rated the stock with a sell rating, fifteen have issued a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $152.88.

In related news, Director Daniel Bradbury sold 600 shares of the stock in a transaction on Monday, November 14th. The stock was sold at an average price of $136.34, for a total value of $81,804.00. Following the completion of the sale, the director now directly owns 17,065 shares of the company’s stock, valued at approximately $2,326,642.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Robert S. Epstein sold 300 shares of the stock in a transaction on Tuesday, September 20th. The shares were sold at an average price of $174.29, for a total value of $52,287.00. Following the completion of the sale, the director now directly owns 6,924 shares of the company’s stock, valued at $1,206,783.96. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

About Illumina

Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

Related posts

Leave a Comment